Archford Capital Strategies LLC Trims Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Archford Capital Strategies LLC trimmed its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 13.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 4,596 shares of the company’s stock after selling 718 shares during the period. Archford Capital Strategies LLC’s holdings in Invesco Biotechnology & Genome ETF were worth $306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Howe & Rusling Inc. purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $31,000. Carnegie Investment Counsel purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $204,000. Jane Street Group LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $295,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Invesco Biotechnology & Genome ETF by 5.6% in the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after buying an additional 299 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of Invesco Biotechnology & Genome ETF by 64.1% during the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after acquiring an additional 2,774 shares during the period.

Invesco Biotechnology & Genome ETF Stock Down 0.3 %

Shares of Invesco Biotechnology & Genome ETF stock opened at $69.04 on Monday. Invesco Biotechnology & Genome ETF has a 52-week low of $59.32 and a 52-week high of $72.84. The company’s 50-day simple moving average is $68.49 and its 200-day simple moving average is $69.17. The firm has a market cap of $278.92 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.